2 No-Brainer Dividend Shares to Purchase in 2026

Dividend shares will not be all the identical. Some will readily lower or droop their payouts on the first signal of bother, whereas others will proceed rising them even throughout market downturns or financial recessions.

Dividend traders favor these which can be within the latter class. Let’s think about two shares alongside these strains which can be price shopping for: Johnson & Johnson (NYSE: JNJ) and Zoetis (NYSE: ZTS). These two healthcare corporations are glorious picks for income-oriented traders.

Will AI create the world’s first trillionaire? Our workforce simply launched a report on the one little-known firm, referred to as an “Indispensable Monopoly” offering the vital know-how Nvidia and Intel each want. Proceed »

Physician talking to patient. — Picture supply: Getty Photographs.

Johnson & Johnson has many qualities that long-term revenue seekers search. The corporate’s enterprise, albeit not significantly thrilling, is constant and resilient. Johnson & Johnson is a number one pharmaceutical firm with an enormous portfolio of accepted medicines, in addition to a medical machine chief working throughout a number of therapeutic areas.

Income and earnings sometimes develop at a good clip. That is the case even when it encounters issues comparable to patent cliffs and government-led drug worth negotiations — points it’s presently coping with, but it surely expects its annual reported gross sales to develop this yr and high $100 billion for the primary time. Johnson & Johnson additionally has a rock-solid steadiness sheet, evidenced by its increased credit standing than the U.S. authorities’s.

Additional, Johnson & Johnson is an progressive firm. It routinely launches new merchandise, each in its biopharma and medtech divisions, that assist it counter stiff competitors, whether or not biosimilar or in any other case.

Johnson & Johnson is now awaiting approval for its robotic-assisted surgical procedure system, the Ottava, that might be an vital development driver over the long term. And the corporate’s pharmaceutical pipeline options a number of dozen ongoing medical trials that can assist it replenish its portfolio and earn vital label expansions.That is how the corporate has carried out properly over the long term.

Lastly, Johnson & Johnson is a Dividend King, an organization with at the least 50 consecutive annual dividend hikes. That is what helps make it an excellent revenue inventory that dividend traders should not suppose twice about.

Zoetis is a number one animal well being firm. It hit some headwinds final yr, as two of its development drivers, Librela and Solensia, which deal with osteoarthritis (OA) ache in canines and cats, respectively, raised security issues; this concern significantly affected Librela.

The excellent news is that the corporate has earned approval for newer merchandise for OA ache in canines and cats, Lenivia and Portela.These two even have the benefit of being longer-acting medicines (administered month-to-month relatively than as soon as each three months) that will possible have stolen market share from their predecessors even with out security issues.

The corporate has maintained a stable place in its trade because of its routinely launching newer and higher merchandise. Its development portfolio additionally options Apoquel, a medication for allergic itch in canines that was a breakthrough in its area of interest. Though it was accepted greater than a decade in the past, Zoetis nonetheless sees room for development in Apoquel, as a big inhabitants of canines stays untreated worldwide.

Zoetis could face challenges attributable to competitors, questions of safety, or patent cliffs, however the firm’s deep portfolio of medicines and progressive method ought to assist it capitalize on an vital development: Youthful generations are more and more selecting proudly owning pets over having kids.

Then there may be the corporate’s dividend, which it has elevated by a formidable 458% over the previous decade. Zoetis is one other terrific healthcare dividend inventory to purchase in 2026 and maintain for some time.

Before you purchase inventory in Johnson & Johnson, think about this:

The Motley Idiot Inventory Advisor analyst workforce simply recognized what they consider are the 10 greatest shares for traders to purchase now… and Johnson & Johnson wasn’t certainly one of them. The ten shares that made the lower might produce monster returns within the coming years.

Contemplate when Netflix made this record on December 17, 2004… for those who invested $1,000 on the time of our advice, you’d have $534,008!* Or when Nvidia made this record on April 15, 2005… for those who invested $1,000 on the time of our advice, you’d have $1,090,073!*

Now, it’s price noting Inventory Advisor’s whole common return is 949% — a market-crushing outperformance in comparison with 190% for the S&P 500. Do not miss the newest high 10 record, out there with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person traders for particular person traders.

See the ten shares »

*Inventory Advisor returns as of March 8, 2026.

Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Idiot has positions in and recommends Zoetis. The Motley Idiot recommends Johnson & Johnson. The Motley Idiot has a disclosure coverage.

2 No-Brainer Dividend Shares to Purchase in 2026 was initially printed by The Motley Idiot